BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 29173655)

  • 21. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
    Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
    Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.
    Wagner M; Samaha D; Khoury H; O'Neil WM; Lavoie L; Bennetts L; Badgley D; Gabriel S; Berthon A; Dolan J; Kulke MH; Goetghebeur M
    Adv Ther; 2018 Jan; 35(1):81-99. PubMed ID: 29270780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
    Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
    Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
    Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
    Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroenteropancreatic Neuroendocrine Tumors.
    Fernandes CJ; Leung G; Eads JR; Katona BW
    Gastroenterol Clin North Am; 2022 Sep; 51(3):625-647. PubMed ID: 36153114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
    Johnson PR
    Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors].
    Chen H; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):982-986. PubMed ID: 28900987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S; Kunz PL
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
    Neychev V; Kebebew E
    Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
    Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
    J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.